Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Stephen P. Stone"'
Autor:
Megha Verma, Stephen I Stone
Publikováno v:
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-5 (2022)
We identified an adolescent young woman with new-onset diabetes. Due to suspicious family history, she underwent genetic testing for common monogenic diabetes (MODY) genes. We discovered that she and her father carry a novel variant of uncertain sign
Externí odkaz:
https://doaj.org/article/c2f8298b73914073b506e3958b59ce6c
Autor:
Damien Abreu, Stephen I. Stone, Toni S. Pearson, Robert C. Bucelli, Ashley N. Simpson, Stacy Hurst, Cris M. Brown, Kelly Kries, Chinyere Onwumere, Hongjie Gu, James Hoekel, Lawrence Tychsen, Gregory P. Van Stavern, Neil H. White, Bess A. Marshall, Tamara Hershey, Fumihiko Urano
Publikováno v:
JCI Insight, Vol 6, Iss 15 (2021)
BACKGROUND Wolfram syndrome is a rare ER disorder characterized by insulin-dependent diabetes mellitus, optic nerve atrophy, and progressive neurodegeneration. Although there is no treatment for Wolfram syndrome, preclinical studies in cell and roden
Externí odkaz:
https://doaj.org/article/cc59812ac3294482ac751139a8922e28
Publikováno v:
Endocrine Connections, Vol 1, Iss 1, Pp 1-5 (2018)
Bilateral adrenal hemorrhages rarely occur during the neonatal period and are often associated with traumatic vaginal deliveries. However, the adrenal gland has highly regenerative capabilities and adrenal insufficiency typically resolves over time.
Externí odkaz:
https://doaj.org/article/5d0c2b99003049619948451d57d9c797
Autor:
Stephen P. Stone
Publikováno v:
Geriatric Dermatology ISBN: 9781003076544
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e121b82c21a38b977fbecd9bc42a692
https://doi.org/10.1201/9781003076544-7
https://doi.org/10.1201/9781003076544-7
Publikováno v:
Journal of Dermatological Treatment. 27:450-455
Treatments for actinic keratosis (AK) can elicit adverse local skin responses (LSRs). Knowledge regarding the burden of AK treatment on health related quality of life (HRQoL) is however limited.To investigate whether treatment of AK improved HRQoL; t
Publikováno v:
Clinics in Dermatology. 32:213-218
Syphilis gained notoriety in the 1500s, when it became widespread throughout Europe. While the origins of syphilis are not certain, recent data have shown that it may have originated in the Americas from a close relative that causes Yaws (Treponema p
Publikováno v:
Dermatology online journal. 22(6)
Myxofibrosarcoma may present as a dermal or subcutaneous nodule, often on the extremity of an elderly patient. We present a case of myxofibrosarcoma on the lower leg of a 77-year-old man, which illustrates the deeply infiltrative growth pattern of th
Publikováno v:
Nielson, Colton; Schutte, Amy; Wilson, Morgan L; & Stone, Stephen P. (2016). Myxofibrosarcoma presenting as an exophytic, multi-lobed nodule on the leg. Dermatology Online Journal, 22(6). Retrieved from: http://www.escholarship.org/uc/item/1jh2b98h
Myxofibrosarcoma may present as a dermal or subcutaneous nodule, often on the extremity of an elderly patient. We present a case of myxofibrosarcoma on the lower leg of a 77-year-old man, which illustrates the deeply infiltrative growth pattern of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbab4de011fa2b03602167956c40cf3f
http://www.escholarship.org/uc/item/1jh2b98h
http://www.escholarship.org/uc/item/1jh2b98h
Publikováno v:
Journal of the American Academy of Dermatology. 56:500-505
A relatively newer class of chemotherapy agents, known as the epidermal growth factor receptor inhibitors (EGF-RIs), is being used to treat advanced stages of solid tumors. Acneiform eruptions are a frequent adverse effect and one which has been asso
Autor:
Kim A. Papp, Charles Camisa, Alice B. Gottlieb, Xiaolin Wang, Stephen P. Stone, Ivor Caro, Patricia A. Walicke, Peter Compton
Publikováno v:
Journal of Cutaneous Medicine and Surgery. 9:313-323
Background: The efficacy and safety of efalizumab have been evaluated in multiple clinical trials. ObjectiveThe purpose of this review is to provide an overview of the safety profile of efalizumab during the clinical trials. Methods: Twelve-week data